Abcam (NASDAQ:ABCM – Get Rating) and Brookline Capital Acquisition (NASDAQ:BCAC – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Valuation and Earnings
This table compares Abcam and Brookline Capital Acquisition’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abcam||$401.06 million||7.97||$5.92 million||N/A||N/A|
|Brookline Capital Acquisition||N/A||N/A||-$480,000.00||N/A||N/A|
Abcam has higher revenue and earnings than Brookline Capital Acquisition.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brookline Capital Acquisition||0||0||0||0||N/A|
Institutional & Insider Ownership
13.9% of Abcam shares are held by institutional investors. Comparatively, 51.8% of Brookline Capital Acquisition shares are held by institutional investors. 6.7% of Abcam shares are held by company insiders. Comparatively, 19.2% of Brookline Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Abcam and Brookline Capital Acquisition’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brookline Capital Acquisition||N/A||-416.32%||-4.75%|
Risk & Volatility
Abcam has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Brookline Capital Acquisition has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Abcam beats Brookline Capital Acquisition on 6 of the 8 factors compared between the two stocks.
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
About Brookline Capital Acquisition
Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.